Genentech's Divarasib Demonstrated Best-In-Class Efficacy, Advancing Standard of Care in Previously Treated KRAS G12C-Mutated Lung Cancer
October 27, 2026
October 27, 2026
SOUTH SAN FRANCISCO, California, Oct. 27 -- Genentech, a member of the Roche Group, issued the following news release:
* * *
Genentech's Divarasib Demonstrated Best-In-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-Mutated Lung Cancer
* Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by . . .
* * *
Genentech's Divarasib Demonstrated Best-In-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-Mutated Lung Cancer
* Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by . . .